甘李药业：上半年归母净利润6.04亿元 同比增长101.96%

Core Viewpoint - Ganli Pharmaceutical (603087) reported significant growth in its financial performance for the first half of 2025, with notable increases in both revenue and net profit [1] Financial Performance - The company achieved a revenue of 2.067 billion yuan, representing a year-on-year growth of 57.18% [1] - The net profit attributable to shareholders reached 604 million yuan, marking a year-on-year increase of 101.96% [1] - Basic earnings per share were reported at 1.02 yuan [1] Product Performance - The sales volume and revenue of insulin preparations in the domestic market showed significant growth during the first half of 2025 [1]